Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations

SIMPLE SUMMARY: Acquired resistance of gastrointestinal stromal tumors (GISTs) to imatinib mesylate (IM) is one of the most critical challenges in GIST therapy. Here we show that a long-term culture of GIST T-1 cells with IM induces clonal heterogeneity resulting in the appearance of cancer cells ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Boichuk, Sergei, Dunaev, Pavel, Skripova, Vera, Galembikova, Aigul, Bikinieva, Firyuza, Shagimardanova, Elena, Gazizova, Guzel, Deviatiiarov, Ruslan, Valeeva, Elena, Mikheeva, Ekaterina, Vasilyeva, Maria, Kopnin, Pavel, Strelnikov, Vladimir, Kiyamova, Ramziya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670741/
https://www.ncbi.nlm.nih.gov/pubmed/38001614
http://dx.doi.org/10.3390/cancers15225354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670741/
https://www.ncbi.nlm.nih.gov/pubmed/38001614
http://dx.doi.org/10.3390/cancers15225354

Ejemplares similares